BrainsWay demonstrates a solid and defensible core business model centered on proprietary Deep TMS technology combined with a lease-based recurring revenue model that enhances customer retention and revenue predictability. Its clinical innovation pipeline and geographic expansion provide credible g…
BrainsWay (BWAY) Q4 2024: 27% Revenue Growth Anchored by Enterprise Expansion and Clinical Innovation
BrainsWay accelerated its commercial momentum in Q4 2024, driven by enterprise account growth and expanding therapeutic indications, reinforcing its leadership in transcranial magnetic stimulation (TMS) therapy. The company’s strategic emphasis on next-generation Deep TMS 360 system development and clinical trials underpins its growth trajectory. Strong cash reserves and a positive operating outlook position BrainsWay for sustained expansion in 2025.
Summary
- Enterprise-Driven Growth: Large institutional partnerships and lease-based models underpin recurring revenue expansion.
- Clinical Innovation Focus: Progress on accelerated treatment protocols and new indications broadens market potential.
- Financial Strength Supports Strategy: Robust balance sheet enables investment in R&D and commercial scale-up.
Business Overview
BrainsWay is a global leader in advanced, noninvasive neurostimulation therapies, primarily through its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform. The company generates revenue by selling and leasing Deep TMS systems used to treat mental health disorders such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and smoking addiction. Its business is segmented across device sales, recurring revenue from leases, and expanding clinical services supported by ongoing research.
Performance Analysis
In Q4 2024, BrainsWay reported revenue of $11.4 million, marking a 27% year-over-year increase, driven by a 25% rise in Deep TMS system placements to 75 units. This growth contributed to a full-year revenue of $41.0 million, up 29% from 2023. The company maintained a strong gross margin of 75%, consistent with prior periods, reflecting stable cost control despite scaling operations. Operating income turned positive at $0.4 million in the quarter, improving from $0.2 million the prior year, while adjusted EBITDA reached $1.4 million, marking the sixth consecutive quarter of profitability on this measure.
Operating expenses increased moderately, with sales and marketing expenses rising slightly to $4.5 million in Q4, reflecting investments in expanding commercial reach, particularly within enterprise accounts. Research and development spending also increased to $2.0 million, supporting clinical trials and next-generation product development. The company’s net income was bolstered by a $1 million non-cash gain related to warrant valuation, resulting in a net income of $1.5 million for the quarter. Cash and equivalents surged to $69.4 million at year-end, fueled by a $20 million equity financing with Valor Equity Partners.
- Enterprise Account Momentum: Large network partnerships drove repeat orders and backlog growth, enhancing sales efficiency.
- Margin Stability Amid Growth: Maintaining a 75% gross margin while scaling reflects operational discipline.
- Cash Position Strength: Robust liquidity supports R&D investments and commercial expansion without debt.
Overall, BrainsWay’s financial performance evidences successful scaling of its Deep TMS platform with improving profitability and a solid foundation for future growth.
Executive Commentary
"We are rapidly growing sales of our Deep TMS system through broadened global channels and have increased our market presence thereby bringing Deep TMS to more patients than ever before. Our relationships with enterprise customers have flourished, resulting in large and recurring agreements that have allowed us to build a robust sales backlog."
Hadar Levy, Chief Executive Officer
"We hit the top end of our guidance with $41 million of revenue recorded for the full year 2024, representing a 29% increase compared to 2023. Adjusted EBITDA was $4.5 million, at the top end of our guidance, representing 11% of revenue."
Ido Marom, Chief Financial Officer
Strategic Positioning
1. Expanding Enterprise Partnerships and Recurring Revenue
BrainsWay’s commercial strategy increasingly targets large institutional customers, which have become a major sales driver. These enterprise accounts provide stability through multi-year agreements and repeat orders, optimizing the return on sales and marketing investments. The lease-based business model further enhances recurring revenue streams, strengthening the company’s financial predictability and customer retention.
2. Advancing Clinical Pipeline and Treatment Indications
The company is advancing a randomized multicenter U.S. clinical trial for an accelerated Deep TMS protocol for MDD, aiming to reduce treatment duration and improve patient convenience. This trial is expected to yield data by Q3 2025. Additionally, BrainsWay is expanding indications, including OCD treatment, elderly depression following FDA label expansion, and exploratory studies in addiction and neurological disorders such as Alzheimer’s and Parkinson’s diseases using the next-generation Deep TMS 360 system.
3. Leveraging Next-Generation Deep TMS 360 System
BrainsWay is preparing to launch a multicenter clinical trial for its Deep TMS 360 system in the second half of 2025, focusing initially on alcohol use disorder (AUD). The device’s novel technology aims to broaden therapeutic applications and enhance treatment efficacy, positioning the company at the forefront of TMS innovation.
4. Geographic Market Expansion
The company has expanded its footprint in key markets including Canada, East Asia, India, and Europe through exclusive distribution agreements and collaborations with large mental health networks. This international growth complements its domestic U.S. expansion and diversifies revenue sources.
5. Strong Financial Position Enabling Strategic Investments
With no debt and $69.4 million in cash and equivalents, BrainsWay is well-capitalized to fund ongoing R&D, clinical trials, and commercial initiatives. The recent $20 million equity infusion from Valor Equity Partners strengthens its ability to invest in long-term growth opportunities and potential collaborations within mental health and addiction sectors.
Key Considerations
BrainsWay’s Q4 and full-year results reflect a transition from early-stage commercialization to scalable growth, supported by operational execution and strategic investments.
- Commercial Execution: The shift towards enterprise accounts is yielding larger, recurring orders and backlog, indicating a maturing sales model.
- Clinical Validation: Ongoing trials and published data are critical to expanding indications and payer acceptance, which will drive adoption.
- Product Innovation: The Deep TMS 360 system represents a strategic inflection point, with potential to unlock new markets and improve patient outcomes.
- Market Dynamics: Positive regulatory developments, such as FDA label expansion for elderly depression, enhance addressable markets.
- Capital Allocation: Strong cash position and disciplined spending enable simultaneous investment in growth and profitability.
Risks
Despite strong momentum, BrainsWay faces risks including the timing and outcome of clinical trials, reimbursement uncertainties especially for new indications, and competitive pressures in the neurostimulation market. Regulatory changes or delays could impact commercialization, while macroeconomic factors may influence customer purchasing behavior. The company’s reliance on enterprise customers also concentrates risk in a smaller customer base.
Forward Outlook
For full-year 2025, BrainsWay guided revenue between $49 million and $51 million, representing 20% to 24% growth over 2024. Management anticipates maintaining gross margins near 75%, with operating income expected between 3% and 4% of revenue and adjusted EBITDA of 11% to 12%. The company highlighted key growth drivers including expanded sales of OCD treatments, accelerated protocols, and next-generation product launches.
Takeaways
BrainsWay is executing a clear strategy to scale its Deep TMS platform by deepening enterprise partnerships and advancing clinical innovation. Its robust financial health supports sustained investment in product development and market expansion. Investors should watch for upcoming clinical trial data in 2025, which could validate accelerated protocols and broaden therapeutic applications, potentially unlocking new revenue streams. The company’s ability to maintain margin stability while growing sales and managing costs will be critical to sustaining profitability amid expansion.
- Commercial Scale-Up: Enterprise accounts and lease models are driving a more predictable and recurring revenue base.
- Innovation Pipeline: Clinical trials and next-gen device development position BrainsWay to address unmet needs in mental health and addiction.
- Financial Discipline: Strong cash reserves and positive EBITDA underpin confidence in executing growth initiatives without compromising profitability.
Conclusion
BrainsWay’s Q4 2024 results underscore its evolution into a profitable, growth-oriented leader in the neurostimulation space. The combination of expanding commercial traction, clinical progress, and strategic investment in innovation sets the stage for continued momentum in 2025 and beyond.
Industry Read-Through
BrainsWay’s performance highlights the growing acceptance of noninvasive neurostimulation therapies as viable treatments for complex mental health disorders. The company’s success in securing large enterprise partnerships and expanding indications signals a maturing TMS market with increasing institutional adoption. The focus on accelerated treatment protocols and next-generation devices reflects broader industry trends toward improving patient convenience and expanding therapeutic reach. Competitors and investors should monitor clinical trial outcomes and reimbursement developments closely, as these factors will shape the competitive landscape and growth potential in neurostimulation and interventional psychiatry.